SA
Create Free Alerts
Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
businesswire.com

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “.

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
businesswire.com

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeti.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
businesswire.com

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first quarter ended December 31, 2025. “Enanta entered the year with significant momentum, advancing our leading RSV treatment portfolio with preparation for a Phase 3 study and expanding our immunology pipeline with the introduction of our.

KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review
defenseworld.net

KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review

KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Insider and Institutional Ownership 95.0% of Enanta

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
businesswire.com

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026. “Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver.

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enanta's President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the event will.

Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
seekingalpha.com

Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development

Enanta Pharmaceuticals (ENTA) remains a "Buy" due to promising secondary endpoints for zelicapavir in RSV, despite missing its primary endpoint. Company's pipeline strength is supported by EDP-323's positive prophylaxis data and robust preclinical immunology programs targeting STAT6 and KIT pathways. The company's strong cash position, now extended into fiscal 2029 after a recent equity raise, ensures continued development of its clinical programs.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
businesswire.com

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025. “This past quarter marked a pivotal period for Enanta, with significant progress across our virology and immunology programs, highlighted by positive topline data from the RSVHR study, our Ph.

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
businesswire.com

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December. Jefferies London Global Healthcare Conference: Fireside Chat on Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET 8th Annual Evercore Healthcare Conf.

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
businesswire.com

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that new data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, its oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 – 22,.

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
businesswire.com

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it's oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 - 22, 20.

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
businesswire.com

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its previously announced underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $10.0.

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
businesswire.com

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of custom.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance